Article
PIK3CA mutations are not a major determinant of resistance to the epidermal growth factor receptor inhibitor cetuximab in metastatic colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research - 1 May 2009
Prenen Hans, De Schutter Jef, Jacobs Bart, De Roock Wendy, Biesmans Bart, Claes Bart, Lambrechts Diether, Van Cutsem Eric, Tejpar Sabine
Abstract excerpt
PURPOSE: It has been reported that activating KRAS mutations negatively affect response to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies in metastatic colorectal cancer. The mutation status of signaling molecules downstream of the EGFR target is thus crucial to predict clinical benefit to EGFR-targeted therapies. Other mechanisms of resistance to EGFR inhibitors could involve activating...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.